Compare HBIO & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBIO | YI |
|---|---|---|
| Founded | 1901 | 2010 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Retail-Drug Stores and Proprietary Stores |
| Sector | Industrials | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 38.1M |
| IPO Year | 2000 | N/A |
| Metric | HBIO | YI |
|---|---|---|
| Price | $0.69 | $2.84 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 555.1K | 16.8K |
| Earning Date | 11-06-2025 | 12-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $87,371,000.00 | ★ $1,908,028,152.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.22 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.28 | $2.48 |
| 52 Week High | $2.28 | $11.35 |
| Indicator | HBIO | YI |
|---|---|---|
| Relative Strength Index (RSI) | 50.05 | 37.39 |
| Support Level | $0.64 | $2.48 |
| Resistance Level | $0.80 | $3.12 |
| Average True Range (ATR) | 0.04 | 0.25 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 25.32 | 29.69 |
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.